SCHOTT Pharma
€24.55Change from previous close: +0.82%Absolute change: +€0.20
At a glance
- Revenue growth
- +3.04%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −2.16%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 14.9%
- FY to Sep 2024: 15.6%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 |
|---|---|---|---|---|
| Total assets | 1,599 | 1,438 | 1,232 | 1,197 |
| Current assets | 681 | 584 | 468 | 555 |
| Cash and equivalents | 22.5 | 23.2 | 24.4 | 28.8 |
| Short-term investments | 3.2 | 3.2 | 1.5 | 1.5 |
| Inventory | 175 | 146 | 139 | 129 |
| Net property, plant and equipment | 786 | 723 | 638 | 517 |
| Goodwill | 28.4 | 29.3 | 29.5 | 31.0 |
| Other intangible assets | 1.3 | 1.1 | 1.5 | 1.9 |
| Long-term investments | 88.5 | 85.1 | 79.1 | 79.8 |
| Current liabilities | 454 | 435 | 351 | 323 |
| Accounts payable | 104 | 95.5 | 90.6 | 99.6 |
| Long-term debt | — | — | — | 0.0 |
| Total debt | 83.0 | 85.8 | 72.3 | 74.8 |
| Total liabilities | 705 | 649 | 540 | 487 |
| Total equity (incl. minority) | 894 | 788 | 692 | 709 |
| Retained earnings | — | — | 37.0 | 682 |
| Minority interest | 2.0 | 1.9 | 1.7 | 1.8 |